Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cardiomyopeptidin
- Development stage
- Phase 4
- Lead developer
- Dalian Zhen-Ao Bio-Tech
- Modality
- Peptides
- Administration
- Intravenous
01
Overview
Cardiomyopeptidin is a peptide active substance extracted from the ventricular myocytes of healthy young pigs. It is being investigated for its cardioprotective effects, aiming to reduce infarct size, preserve viable myocardium, and improve microcirculation following myocardial injury, particularly in patients with acute ST-segment elevation myocardial infarction. It is also being explored for its cardioprotective effect in ICU patients with non-organic heart disease.
- Other names
- Cardiopeptidin
Beyond the preview
Go deeper on cardiomyopeptidin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cardiomyopeptidin.